Stability of lansoprazole in extemporaneously compounded suspensions for nasogastric or oral administration

Canadian Journal of Hospital Pharmacy

Volumn 60, Issue 3, 2007, Pages 184-191

  Ensom, Mary H H ^a,b   Decarie, Diane ^b   Sheppard, Ian ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

High performance liquid chromatography; Pediatrics; Proton pump inhibitors

Indexed keywords

BICARBONATE; LANSOPRAZOLE; PANTOPRAZOLE; SODIUM HYDROXIDE; SWEETENING AGENT;

ADULT; ARTICLE; BITTER TASTE; CLINICAL TRIAL; COLOR; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG DEGRADATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; NASOGASTRIC DRUG ADMINISTRATION; NORMAL HUMAN; ODOR; PH; PRECIPITATION; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; STORAGE TEMPERATURE; SUSPENSION; TASTE AVERSION;

EID: 34447500432     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003;63(24):2739-2754.
2. Bown RL. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. Int J Clin Pract 2002;56(2):132-139.
3. Health Canada approves pediatric indication for Prevacid (lansoprazole) for children with gastroesophageal reflux disease. Doctor's Guide Publishing Ltd; 2005 Feb 10 [cited 2006 Aug 28]. Available from: http://www.pslgroup.com/dg/24A196.htm
4. Lansoprazole. In: Drug product database (DPD). Ottawa (ON): Health Canada; [cited 2006 Aug 28]. Available from: http://search.hc-sc.gc.ca/ cgi-bin/query?mss=hc%2Fdpd%2Fenglish%2Factive%2F simple&pg=q&what=web&kl=XX&enc=iso88591&site= main&filter=product&q=lansoprazole
5. Sharma VK, Ugheoke EA, Vasudeva R, Howden CW. The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules. Aliment Pharmacol Ther 1999;12(11):1171-1174.
6. Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension - a liquid formulation of lansoprazole - effectively suppresses intragastric acidity when administered through a gastrostomy. Am J Gastroenterol 1999;94(7):1813-1817.
7. Sharma VK, Peyton B, Spears T, Raufman JP, Howden CW. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther 2000;14(7):887-892.
8. Chun AH, Erdman K, Chin YL, Pilmer BL, Achari R, Cavanaugh JH. Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation. Clin Ther 2002;24(8):1322-1331.
9. DiGiacinto JL, Olsen KM, Bergman KL, Hoie EB. Stability of suspension formulations of lansoprazole and omeprazole stored in amber-colored plastic oral syringes. Ann Pharmacother 2000; 34(5):600-605.
10. Doan TT, Wang Q, Griffin JS, Lukasik NL, O'Dea RF, Pan WJ. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am J Health Syst Pharm 2001;58(16):1512-1519.
11. Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005;44(5):441-466.
12. Dentinger PJ, Swenson CF, Anaizi NH. Stability of pantoprazole in an extemporaneously compounded oral liquid. Am J Health Syst Pharm 2002;59(10):953-956.
13. Fan E, Gavura S, Ruddock B. Proton pump inhibitors in pediatric patients. Can Pharm J 2006:139(5):53-55.